OncoMatch/Clinical Trials/NCT06860971
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
Is NCT06860971 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies AL2846 Capsules for thyroid cancer.
Treatment: AL2846 Capsules — This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong progression - free survival (PFS) compared with placebo.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: VEGFR inhibitor
Disease progression (per RECIST 1.1) after receiving no more than 2 lines (no more than 3 types) lines of Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) therapy
Cannot have received: other anti-tumor clinical trial drugs
Subjects who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before randomization.
Lab requirements
Blood counts
Hemoglobin (HGB) ≥90 g/L; Absolute neutrophil count (NEUT) ≥1.5×10⁹/L; Platelet count (PLT) ≥90×10⁹/L
Kidney function
Creatinine clearance (CCR) ≥50 mL/min
Liver function
Total bilirubin (TBIL) ≤1.5×ULN; ALT and AST ≤2.5×ULN
Laboratory parameters: HGB ≥90 g/L; NEUT ≥1.5×10⁹/L; PLT ≥90×10⁹/L; TBIL ≤1.5×ULN; ALT and AST ≤2.5×ULN; CCR ≥50 mL/min; PT, APTT, INR ≤1.5×ULN (without anticoagulation therapy); ALB ≥30 g/L (no albumin infusion within 7 days prior to screening).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06860971 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior other anti-tumor clinical trial drugs disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify